Jake’s Story

Jake, an active 13-year-old, enjoyed playing basketball, so when he complained of his shoulder hurting, I didn't think too much about it. We figured he had just pulled a muscle. But when his other shoulder started hurting a week later, my instincts told me that this wasn't quite right and so off we went to the doctor. This was the beginning of our new normal.

After numerous tests, we found out he had leukemia. Once the initial shock wore off, we learned we had important treatment decisions to make, and this was when The Leukemia & Lymphoma Society (LLS) became an invaluable resource. Not knowing much about leukemia, we relied on LLS's free booklets, educational teleconferences and www.LLS.org to learn about the disease, its different treatments and how to cope with a blood cancer diagnosis.

Since his diagnosis, Jake has had to deal with hundreds of appointments and dozens of spinal taps, yet through it all he has had maintained a good sense of humor. I am the proudest mother in the world, knowing that my brave son is learning so much from this experience, and I cannot wait to see what special future awaits him.

Although Jake still has two more years of treatment, he is ready to go back to school. Once again LLS is providing assistance. Their Trish Greene Back to School Program educates teachers and other students so young cancer patients have a smoother transition when they're well enough to return to school.

--Christine Brantley

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap